Novo Nordisk's Paediatric Data Lands With a Thud as Investors Keep Eyes Fixed on London

Despite strong STEP-Young results, Novo Nordisk shares stay flat as investors weigh pipeline setbacks and patent cliff ahead of London CMD.

The clinical news was about as good as it gets. The market reaction? Barely a shrug.

Novo Nordisk revealed on Wednesday that 40.4 percent of children aged six to under 12 treated with once-weekly semaglutide in the Phase 3 STEP-Young trial were no longer classified as obese after 68 weeks. In the placebo arm, that figure stood at zero percent. The company said the safety profile aligned with data from adult and adolescent studies, with no concerns flagged around growth or pubertal development.

It is a striking result that pushes the Danish drugmaker's blockbuster franchise into an age bracket the pharmaceutical industry has long considered commercially marginal. Yet the shares barely stirred — down 0.2 percent on the day to EUR 39.99 — underscoring just how deeply investor scepticism has taken root.

A Stock That Refuses to Catch a Bid

The muted response to headline paediatric efficacy data fits a pattern that has defined Novo Nordisk's equity story for much of 2025. The stock is down 9.2 percent since the start of the year and 14 percent over twelve months. It sits 27 percent below its 52-week high of DKK 54.86, reached in January. The 50-day moving average stands at EUR 41.60, the 200-day at EUR 40.15 — the shares hover just beneath the latter, trapped in a sideways band that reflects a market unable to decide between competing narratives.

One price move from last week captures the mood neatly. When the oral formulation of semaglutide launched in Germany on Friday — the largest pharma market in Europe, following earlier approvals in Greater China — the stock slipped 0.7 percent. Marketers of old would have expected a bounce; instead, the launch was priced in as routine.

Buybacks Signal Confidence, Not Price Support

Behind the scenes, management continues to put its money where its mouth is. The buyback programme, running since February 4, has seen Novo Nordisk repurchase roughly 32 million B-shares at an average price of DKK 281.63, for a total outlay of just over DKK 9 billion through September 4. The company now holds around 46 million of its own B-shares, equivalent to one percent of share capital. The programme is scheduled to run until early February 2027 and is sized at DKK 15 billion in total.

That is a meaningful statement of self-belief — but it has done little to arrest the share price slide. The stock currently trades at EUR 39.80, having fallen 9.6 percent year-to-date in one source's accounting, with the twelve-month decline pegged at 14 percent.

The Analyst Divide: Two Houses, Two Worlds

The conflicting signals from the sell-side help explain why the stock cannot find direction. Deutsche Bank cut its rating to Sell from Hold on August 27, slashing its price target to DKK 265. The bank cited weakening growth prospects for 2027, pipeline setbacks — most notably the late-stage failure of Ziltivekimab — and the looming risk of patent expiry later in the decade. It reaffirmed that Sell stance on September 2.

JPMorgan, by contrast, raised its price target from DKK 250 to DKK 275 on August 25, maintaining a Neutral rating. The US bank lifted its 2026 revenue forecast by 5 percent, betting on more limited generic erosion for Ozempic and more favourable US price adjustments than the bears anticipate.

Two credible houses, two diametrically opposed conclusions. The former looks at the patent cliff and a disappointed cardiovascular pipeline; the latter sees pricing power at the existing blockbusters that has yet to break. Both arguments carry weight — and the share price, oscillating in a narrow channel, reflects the stand-off.

What London Must Deliver

The next real test arrives on September 21, when Novo Nordisk hosts its capital markets day in London. Management is expected to lay out fresh strategic ambitions alongside a comprehensive review of the pipeline, operations and performance. For a company whose stock trades below its own 200-day average despite operationally solid growth, the event represents an opportunity to reconcile scientific momentum with capital-market reality.

The STEP-Young data will feature in that narrative as evidence of the semaglutide franchise's long-term durability. But they do little to resolve the nearer-term questions over growth velocity and competitive pressure that have come to dominate the investment debate.

There is, of course, a broader societal dimension that extends well beyond the trading screen. The prospect of weight-loss pharmacology moving into ever-younger patient populations raises questions regulators, parents and physicians will increasingly have to confront. With the STEP-Young results, Novo Nordisk has planted a flag in that territory — and the conversation it triggers may ultimately matter more than any single quarter's earnings. For now, though, the market's focus is narrower: whether the London showcase can supply the clarity needed to break the stock out of its rut. Until then, the shares look likely to remain stuck in their tight range — clinical triumphs notwithstanding.